e-learning
resources
ERJ
2014
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy
Yoo Jung-Wan, Jo Kyung-Wook, Kang Bo-Hyung, Kim Mi Young, Yoo Bin, Lee Chang-Keun, Kim Yong-Gil, Yang Suk-Kyun, Byeon Jeong-Sik, Kim Kyung-Jo, Ye Byong Duk, Shim Tae Sun
Source:
Eur Respir J 2014; 44: 1289-1295
Journal Issue:
November
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Yoo Jung-Wan, Jo Kyung-Wook, Kang Bo-Hyung, Kim Mi Young, Yoo Bin, Lee Chang-Keun, Kim Yong-Gil, Yang Suk-Kyun, Byeon Jeong-Sik, Kim Kyung-Jo, Ye Byong Duk, Shim Tae Sun. Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy. Eur Respir J 2014; 44: 1289-1295
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Salivary SLPI and disease severity in bronchiectasis
Risk score of drug-induced liver injury among new tuberculosis patients
PG19 Heart-lung interaction
Related content which might interest you:
Tumor necrosis factor alpha inhibitors and reactivation of tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 281s
Year: 2007
Screening for latent tuberculosis before tumour necrosis factor antagonist therapy
Source: Eur Respir J 2015; 45: 1512-1513
Year: 2015
Screening for latent tuberculosis before tumour necrosis factor antagonist therapy
Source: Eur Respir J 2015; 45: 1510-1512
Year: 2015
Screening and monitoring of tuberculosis in patients on tumor necrosis factor antagonist therapy
Source: Annual Congress 2011 - Clinical challenges in tuberculosis
Year: 2011
The risk of tuberculosis related to tumour necrosis factor antagonist therapies
Source: Annual Congress 2011 - TBNET: tuberculosis research in Europe
Year: 2011
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
Source: Eur Respir J 2010; 36: 1185-1206
Year: 2010
Tuberculosis and tumor necrosis factor alpha antagonist: Our experience
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012
A screening for latent tuberculosis infection among candidates to anti-tumor necrosis factor-alpha agents using a whole blood interferon-gamma test
Source: Annual Congress 2008 - Interferon-gamma release assay tests for diagnosing tuberculosis infection and disease
Year: 2008
Tumor necrosis factor α in chronic pulmonary diseases of children
Source: Eur Respir J 2002; 20: Suppl. 38, 193s
Year: 2002
The levels of tumour necrosis factor-alpha and interleukin-1 in newly diagnosed and multi drug resistant tuberculosis
Source: Annual Congress 2004 - Clinical and diagnostic features of tuberculosis
Year: 2004
Tumour necrosis factor gene polymorphisms and childhood wheezing
Source: Eur Respir J 2005; 26: 637-646
Year: 2005
Effects of zinc on the interleukin-1 and tumor necrosis factor in experimental silicosis
Source: Eur Respir J 2002; 20: Suppl. 38, 517s
Year: 2002
Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial
Source: Eur Respir J 2014; 43: 295-298
Year: 2004
Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma in lung cancer complicated with metastatic pleurisy
Source: Eur Respir J 2001; 18: Suppl. 33, 233s
Year: 2001
Pulmonary infections in patients receiving treatment of tumor necrosis factor alpha antagonists
Source: International Congress 2015 – Immunodepression and severe pneumonia
Year: 2015
Pulmonary lesions in patients with inflammatory bowel disease – the baseline and under anti-tumor necrosis factor therapy.
Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases
Year: 2017
Implication of leptin, tumor necrosis factor-alpha, interleukin-1 and interleukin-6 in the pathogenesis of wasting in tuberculosis
Source: Annual Congress 2006 - Immunology of tuberculosis and diagnosis of tuberculosis infection
Year: 2006
The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis
Source: Eur Respir J 2006; 28: Suppl. 50, 542s
Year: 2006
Tumour necrosis factor and lymphotoxin A polymorphisms: a relationship with COPD and its progression?
Source: Eur Respir J 2007; 29: 8-10
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept